국내 골관절염 및 류마티스관절염 치료를 위한 Celecoxib의 비용-효과성 연구
The Cost Effectiveness of Celecoxib versus Diclofenac and Omeprazole in Patients with Osteoarthritis or Rheumatoid Arthritis
1
조회
0
다운로드
0
인용
0
참고문헌
초록
Objectives: The aim of this study is to analyze cost-effectiveness of celecoxib monotherapy versus diclofenac and omeprazole combination therapy for osteoarthritis or rheumatoid arthritis patients in Korea. Methods: A 6-month decision tree model was developed from the limited societal per- spective. The main efficacy probabilities were derived from the CONDOR trial which studied the efficacy and adverse event rates for rheumatoid arthritis and osteoarthritis patients with the use of non-steroidal anti-inflammatory drugs. The model was conducted on a 3-month cycle until the first event and one-month cycle thereafter. Gastrointestinal event rates were applied along with mortality and utility values to get the final results. Costs included medications, monitoring and treatment costs for adverse events. All cost information was obtained from Korea-specific data sources. Sensi- tivity analysis was conducted to reflect compliance rate, patient age and celecoxib price change ac- cording to the current drug pricing policy in Korea. Results: The final cost and quality-adjusted life year (QALY) of celecoxib was 409591 KRW with 0.43064 QALY and 426645 KRW with 0.42539 QALY for diclofenac plus omeprazole. The celecoxib total cost was less costly than diclofenanc plus omeprazole while it yielded more QALY gained, thus celcecoxib was a dominant treatment option. Sensitivity analysis results were robust and proved celecoxib was cost effective. Conclusion: Cele- coxib can be considered as a cost-effective measure compared to difclofenac plus omeprazole thera- py in patients with osteoarthritis and rheumatoid arthritis.
Abstract
Objectives: The aim of this study is to analyze cost-effectiveness of celecoxib monotherapy versus diclofenac and omeprazole combination therapy for osteoarthritis or rheumatoid arthritis patients in Korea. Methods: A 6-month decision tree model was developed from the limited societal per- spective. The main efficacy probabilities were derived from the CONDOR trial which studied the efficacy and adverse event rates for rheumatoid arthritis and osteoarthritis patients with the use of non-steroidal anti-inflammatory drugs. The model was conducted on a 3-month cycle until the first event and one-month cycle thereafter. Gastrointestinal event rates were applied along with mortality and utility values to get the final results. Costs included medications, monitoring and treatment costs for adverse events. All cost information was obtained from Korea-specific data sources. Sensi- tivity analysis was conducted to reflect compliance rate, patient age and celecoxib price change ac- cording to the current drug pricing policy in Korea. Results: The final cost and quality-adjusted life year (QALY) of celecoxib was 409591 KRW with 0.43064 QALY and 426645 KRW with 0.42539 QALY for diclofenac plus omeprazole. The celecoxib total cost was less costly than diclofenanc plus omeprazole while it yielded more QALY gained, thus celcecoxib was a dominant treatment option. Sensitivity analysis results were robust and proved celecoxib was cost effective. Conclusion: Cele- coxib can be considered as a cost-effective measure compared to difclofenac plus omeprazole thera- py in patients with osteoarthritis and rheumatoid arthritis.
참고문헌 (17)
- 백승훈, "골관절염의 약물요법", 대한의사협회지, 56(12), pp.1123~1131 (2013), 대한의사협회
- Laine L, "GI risk and risk factors of NSAIDs", J Cardiovasc Pharmacol, 47(Suppl 1), pp.S60~S66 (2006)
- 김정욱, "비스테로이드소염제 유발 위창자병증", 대한소화기학회지, 52(3), pp.134~141 (2008), 대한소화기학회
- "2013 Statistical Yearbook" (2014)[URL]
- 정대영, "비출혈 소화성궤양 치료의 가이드라인", 대한소화기학회지, 54(5), pp.285~297 (2009), 대한소화기학회
- 김상균, "소화성궤양의 진단 가이드라인", 대한소화기학회지, 54(5), pp.279~284 (2009), 대한소화기학회
- Chan FK, "Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial", Lancet, 376, pp.173~179 (2010)
- Singh G, "Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study", Am J Med, 119, pp.255~266 (2006)
- "Mortality Census by Gender and Age (5 years) Mortality (1983-2013)" (2014)[URL]
- 이기상, "상부 위장관 출혈을 보인 노인환자의 임상적 특성", Annals of geriatric medicine and research, 15(3), pp.170~180 (2011), 대한노인병학회
- Yen ZS, "Cost-effectiveness of treatment strategies for osteoarthritis of the knee in Taiwan", J Rheumatol, 31, pp.1797~1803 (2004)
- Maetzel A, "The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis", Arthritis Rheum, 49, pp.283~292 (2003)
- Spiegel BM, "Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups", Arthritis Rheum, 53, pp.185~197 (2005)
- "Reimbursement Price List" (2015)[URL]
- "2014 First Weighted Average Price" (2014)[URL]
- "2015 Medical, Dental, Oriental Official Fee for Service List"[URL]
- Kellner HL, "Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial", Curr Med Res Opin, 28, pp.1537~1545 (2012)